Navigation Links
Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
Date:8/31/2008

Sub-group analysis of landmark trial showed prasugrel substantially reduced risk of heart attack and stent thrombosis compared with clopidogrel among

ACS patients with diabetes

MUNICH, Germany, Aug. 31 /PRNewswire-FirstCall/ -- Patients who were diabetic and diagnosed with acute coronary syndromes (ACS) were 40 percent less likely to suffer a heart attack if they were treated with prasugrel vs. clopidogrel, according to a sub-group analysis of the TRITON-TIMI 38 trial (8.2 percent vs. 13.2 percent, P<0.001). In addition, according to this same analysis, the combined rate of cardiovascular death, non-fatal heart attack and non-fatal stroke was reduced by 30 percent in diabetes patients treated with prasugrel compared to those treated with clopidogrel (12.2 percent vs. 17.0 percent, P<0.001). In patients without diabetes, there was also improvement in outcomes with prasugrel, with the primary endpoint occurring in 9.2 percent of patients treated with prasugrel and 10.6 percent of patients treated with clopidogrel (P=0.02).

The diabetic sub-group analysis was presented today by Stephen Wiviott, M.D., Assistant Professor of Medicine at Harvard Medical School and investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham & Women's Hospital, Boston, USA, at the Congress of the European Society of Cardiology (ESC) in Munich, Germany. In addition, the manuscript was simultaneously published online in Circulation, the medical journal of the American Heart Association (AHA).

"The results observed from this sub-group analysis showed that antiplatelet therapy with prasugrel resulted in significantly greater reduction of cardiovascular events among patients with diabetes when compared to those who were treated with clopidogrel," said Wiviott.

The reduction of cardiovascular events was consistent across the sub-group of diabetes patients regardless of diabetic therapies (insulin versus no insu
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
2. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
3. TRITON-TIMI 38 Stent Analysis Favors Prasugrel
4. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
5. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
6. Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies
7. Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients Day
8. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
9. Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Variant of Mad Cow Disease May Be Transmitted by Blood Transfusions, According to Animal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Echo Therapeutics, Inc. ... company focused on skin permeation, continuous glucose monitoring ... W. Hollander has been appointed Chief Executive ... more than 20 years of experience in the ... most recently served as Vice President, Business Development, ...
(Date:12/24/2014)... ResMed (NYSE: RMD ) today announced ... medical device manufacturer BMC Medical Co., Ltd. ... listed below infringe ResMed,s patents, and entered an order prohibiting ... the United States : , iVolve ... Willow nasal pillows mask , iVolve full face mask ...
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... , MELBOURNE, Australia, Sept. 3 Cytopia Limited,s ... passed US Food and Drug Administration (FDA) review. CYT387 is ... haematological disorders. The company,s IND application is now active and ... in the United States. , , CYT387 ...
... Hedgehog trial results suggest antitumor activity in basal cell skin cancer ... A study published today in the New England Journal of ... metastatic basal cell skin cancer tested at the Virginia G. Piper ... tumor shrinkage and limited side effects in patients. , , ...
Cached Medicine Technology:Cytopia's CYT387 Receives FDA Clearance to Start US Clinical Trials 2Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 2Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 3Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine 4
(Date:12/26/2014)... “Many people become overwhelmed by the thought ... and phone calls with insurance companies,” The Jones Firm ... free eBook on pedestrian and bicycle accidents . ... bicycle auto accident claims assures the injured individual that ... handling their case while they focus on recovering. ...
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
(Date:12/25/2014)... 2014 Recently, iFitDress.com, the popular online supplier ... announced its new selection of black one-shoulder cocktail dresses ... now; they are available at discounted prices, up to 70% ... will last for three weeks only. You know, we have ... are interested in our new items can visit our website ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 BambooFlooringChina.com sells ... high quality bamboo flooring. Today, the company announces ... in many styles and colors. , BambooFlooringChina.com is the ... CEO, the promotion is valid until Jan. 20, 2015. ... strips and woven with a natural thread. All the ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... , , , ... a hospitalist management company, presented performance improvement and cost savings ... Services during the recent American Hospital Association (AHA) Leadership Summit. ... President, Medical Affairs at Reid, presented average three-month-trend results of ...
... TAMPA, Fla., Aug. 6 Gold Standard/Elsevier ... launch of three MedCounselor consumer drug information modules for pharmacies ... how to take medications safely, assists in identifying unknown tablets ... are indispensable in helping to increase consumer compliance to their ...
... , NEW YORK, Aug. 6 ... shown to significantly help improve the appearance of unwanted discoloration, age ... select physicians to help their patients achieve picture perfect skin. A ... in leading physician offices for $120 per 1 ounce pump. , ...
... solid year-to-date performance and, positive outlook for the remainder ... SXC Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: SXCI ... periods ended June 30, 2009. Financial references are in U.S. dollars unless ... ------------------, - Revenue was ...
... , , , ... Aug. 6 Stereotaxis, Inc. (Nasdaq: STXS ) today reported ... Revenue for the recent second quarter totaled $12.6 million, an increase of ... During the quarter, the Company recognized revenue on eight Niobe(R) Magnetic ...
... ... insurance costs is essential if we expect to create jobs and rebuild the economy says ... Los ... as insurance costs run amok and further sideline a failing economy, according to President Obama. ...
Cached Medicine News:Health News:Inpatient Management, Inc. and Reid Hospital Achieve Performance Improvement and Cost Savings 2Health News:Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules 2Health News:Gold Standard/Elsevier Launches MedCounselor Consumer Drug Information Modules 3Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 2Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 3Health News:SXC Health solutions announces record second quarter financial results 2Health News:SXC Health solutions announces record second quarter financial results 3Health News:SXC Health solutions announces record second quarter financial results 4Health News:SXC Health solutions announces record second quarter financial results 5Health News:SXC Health solutions announces record second quarter financial results 6Health News:SXC Health solutions announces record second quarter financial results 7Health News:SXC Health solutions announces record second quarter financial results 8Health News:SXC Health solutions announces record second quarter financial results 9Health News:SXC Health solutions announces record second quarter financial results 10Health News:SXC Health solutions announces record second quarter financial results 11Health News:SXC Health solutions announces record second quarter financial results 12Health News:SXC Health solutions announces record second quarter financial results 13Health News:SXC Health solutions announces record second quarter financial results 14Health News:SXC Health solutions announces record second quarter financial results 15Health News:SXC Health solutions announces record second quarter financial results 16Health News:SXC Health solutions announces record second quarter financial results 17Health News:SXC Health solutions announces record second quarter financial results 18Health News:SXC Health solutions announces record second quarter financial results 19Health News:Stereotaxis Reports 19% Second Quarter Revenue Growth 2Health News:Stereotaxis Reports 19% Second Quarter Revenue Growth 3Health News:Stereotaxis Reports 19% Second Quarter Revenue Growth 4Health News:Stereotaxis Reports 19% Second Quarter Revenue Growth 5Health News:Stereotaxis Reports 19% Second Quarter Revenue Growth 6Health News:Stereotaxis Reports 19% Second Quarter Revenue Growth 7Health News:Stereotaxis Reports 19% Second Quarter Revenue Growth 8Health News:Sinking Economy Hit Hard by Soaring Healthcare Costs, Says MedicareSupplementPlans.com 2
... designed for patient comfort as well as dependable ... at 5cm intervals and line marked each centimeter., ... available spanning most clinical needs and the range ... or two sensors., ,Flexilog single-use catheters are ...
... UES catheter is made of two probes ... choice of sensor distance., ,VersaFlex disposable ... ,Alpine's VersaFlex catheters are the smallest ... French), and are the perfect combination of ...
... Slimline single-use pH catheters are ... cross-contamination and allow greater patient comfort ... ,Medtronic pH measurement systems have been ... that allow an accurate room-temperature calibration. ...
FLEXILOG spare part....
Medicine Products: